The EMBRAVE Study
for children with early-onset SCN2A Developmental and Epileptic Encephalopathies (DEE)
Thank you for your interest in the PRAX-222-111 EMBRAVE study for children with SCN2A early-onset Development and Epileptic Encephalopathy (DEE). Enrollment into the Part 1 cohort of the EMBRAVE study has concluded. To learn the latest updates on the EMBRAVE study, you can read Praxis’ press release linked below.
If you would like to be notified when the next phase of the EMBRAVE study is initiated, please schedule a call with our Nurse Patient Navigator.
PRAX-222 is an investigational antisense oligonucleotide (ASO) with the potential to be the first disease-modifying treatment for early-onset SCN2A Developmental and Epileptic Encephalopathy (DEE).
An ASO is a short, synthetic segment of genetic sequence designed to correct the malfunction in a specific gene. In animal studies, PRAX-222 was shown to significantly reduce seizures, normalize developmental curves and improve survival. By targeting the underlying genetic cause of disease, PRAX-222 has demonstrated potential to go beyond seizures to treating other symptoms of the disease.
Speak to a nurse about the EMBRAVE Study
To schedule call with a Praxis Nurse Patient Navigator:
Please review and complete the consent checkbox below.
Once you check the box a calendar will open, and you can select a day and time to speak with the EMBRAVE nurse navigator.
By clicking the above box and filling out the information, you consent to providing this information to Praxis Precision Medicines, Inc. (Praxis) and its employees, affiliates, and service providers. You understand that your information will be used to enable Praxis to engage in prescreening for the research study. You permit Praxis to share your information with third parties, including the Sites, Clinical Research Organizations, the Eligibility Review Board, and regulatory or public health agencies, in order to evaluate your eligibility for the research study.
Additionally, with this consent, Praxis will retain such information to provide you with updates, newsletters and communication related to Praxis™ ongoing studies and business updates.